Brooklyn, N.Y.’s Maimonides Medical Center has become the second hospital in the United States and the first on the East Coast to acquire the groundbreaking Focal One high-intensity focused ultrasound technology, the world’s most advanced non-invasive prostate ablation device. Maimonides Medical Center urologists were recently trained on the use of Focal One and will begin to schedule the outpatient treatments for eligible patients with localized prostate cancer in February 2019.
“I have long been convinced that focal therapy is potentially an ideal option for some men with prostate cancer, in much the same way lumpectomy has replaced complete ablation of the breast for many women with breast cancer,” said David A. Silver, M.D., chief of urology at Maimonides Medical Center and director of the Maimonides Prostate Center. “Shortly after Focal One was cleared by the FDA, I saw HIFU treatments in Montreal, where physicians have treated more than 100 patients. It was clear to me that Focal One was the perfect tool to achieve a focal ablation, meaning we can treat the cancer, preserve the prostate and enable our patients to maintain their quality of life. The move from whole-gland therapy to focal therapy represents a real paradigm shift in the way we approach prostate cancer.”
Implementing Focal One is consistent with the hospital’s goal of continuously enriching and expanding its services with the most leading-edge technology available to meet the needs of its patients.
“At Maimonides Medical Center, we’re delighted to be the first on the East Coast to acquire this breakthrough technology,” said Kenneth Gibbs, president and CEO of Maimonides. “When our cancer experts told us that this is a game-changer for many of our prostate cancer patients, we did not hesitate. This precision technology clearly places our program among the most advanced in the world—right here in Brooklyn, N.Y.”
“We are extremely enthusiastic to count Maimonides Medical Center as the first to embrace our Focal One technology in the Eastern U.S., commented Marc Oczachowski, chief executive officer of EDAP TMS. “Shortly after the first U.S. device sold a few weeks ago, this new Focal One sale confirms the appeal our technology represents for the U.S. market.”
Maimonides Medical Center is nationally recognized for clinical excellence across all major specialties. Our accomplished physicians are known for innovation and strengthening our teaching and research programs. With 711 beds, the medical center is dedicated to bringing patients the most advanced care available—anywhere. Maimonides continues to grow in response to evolving models of care and the needs of our communities, and is home to Brooklyn’s only full-service cancer center and its only children’s hospital. According to the federal government, Maimonides is a “Top 10” hospital nationally for patient survival rates.
To learn more about the clinical programs at Maimonides, please visit www.maimonidesmed.org.